JPWO2021207281A5 - - Google Patents

Claims (19)

A vaccine comprising virus-like particles comprising E6020 and a coronavirus virus antigen and at least one additional adjuvant, wherein the at least one additional adjuvant is an aluminum-based adjuvant. The vaccine of claim 1, wherein the vaccine contains 0.01 mg to 5 mg of the at least one additional adjuvant. The vaccine of claim 1, wherein the vaccine comprises 0.1 mg/mL to 0.9 mg/mL of the at least one additional adjuvant. 2. The vaccine of claim 1, wherein the at least one additional adjuvant is selected from the group consisting of an aluminum hydroxide adjuvant, an aluminum phosphate adjuvant, an aluminum salt , a chemokine, a cytokine, a nucleic acid sequence, a lipoprotein, a lipopolysaccharide, monophosphoryl lipid A, lipoteichoic acid, imiquimod, resiquimod, QS-21, and any combination thereof. The vaccine of claim 1, wherein the vaccine is formulated as microparticles or nanoparticles. A vaccine comprising E6020 and a virus-like particle comprising an antigen. The vaccine of claim 6 , wherein the antigen is derived from influenza or coronavirus. The vaccine of claim 6 , wherein the virus-like particle comprises a Gag protein of a murine leukemia virus. 7. The vaccine of claim 6, wherein the vaccine comprises at least one additional adjuvant selected from the group consisting of an aluminum hydroxide adjuvant, an aluminum phosphate adjuvant, an aluminum salt, a chemokine, a cytokine, a nucleic acid sequence, a lipoprotein, a lipopolysaccharide, monophosphoryl lipid A, lipoteichoic acid, imiquimod, resiquimod, QS- 21 , and any combination thereof. 10. The vaccine of claim 9 , wherein the vaccine comprises 50 μg to 50 mg of the at least one additional adjuvant. The vaccine of any one of claims 1 to 10, wherein the antigen is a SARS-CoV-2 spike protein having an amino acid sequence according to any one of SEQ ID NOs: 1 to 4. The vaccine of any one of claims 1 to 11 , wherein the vaccine comprises from 1.0 mg to 5.0 mg of the at least one additional adjuvant. The vaccine of any one of claims 1 to 12, wherein the vaccine contains 1 μg to 50 μg of E6020. The vaccine of any one of claims 1 to 13, wherein the virus-like particle comprises 10 μg to 10 mg of Gag protein. The vaccine of any one of claims 1 to 14, wherein the vaccine is formulated in a buffer solution. The vaccine of any one of claims 1 to 14, wherein the vaccine is formulated as an emulsion. The vaccine of any one of claims 1 to 16 for generating an immune response in a subject in need of prevention or amelioration of a viral infection. 18. The vaccine of claim 17, wherein the vaccine is adapted to be administered in a dose ranging from 0.1 mL to 10 mL. 19. The vaccine of claim 17 or 18, wherein the vaccine is adapted to be administered intranasally, intravenously, intradermally, intramuscularly or subcutaneously to the subject.